Phase 3 clinical program for the treatment of ulcerative colitis
Abivax’s lead product candidate obefazimod is currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis (“ABTECT program”) with the first patient enrolled in the United States in October 2022.
1,200 UC patients across 36 countries will take part in the pivotal Phase 3 program that consists of two induction trials and a single subsequent maintenance trial (ABTECT-1 (ABX464-105) and ABTECT-2 (ABX464-106) induction trials and ABTECT maintenance trial (ABX464-107)).
To check the current status of the trials of our ABTECT program, the list of clinical trial sites open for recruitment and for further information, please visit clinicaltrials.gov where you will find all relevant details on the induction studies ABTECT-1 and ABTECT-2 as well as on the ABTECT maintenance trial.
If you are a healthcare professional and interested in further information, please send an email to ABTECT@abivax.com.
If you are a patient and potentially interested in participating in the ABTECT program, please talk to you treating physician or gastroenterologist who will be able to provide further guidance.